Member Info for The_Paladin

"I say to myself if the company had no future why would TP, TM, Prof and Mr C, Doc D and Ghia keep posting."

An odd statement to say the least?

It would be equally silly for me to state that if the company had no future, why does TD_19 keep posting?

Additionally, why choose six forum contributors at random and group them together in a meaningless comment? Or are you suggesting something here? I cannot make sense of your silly comment without further clarification?

“At what point do the 'clever people' on here realise we have nothing?”

The words of a “glass half empty” person. As ever, factually, one cannot dispute this contributor’s words. An more optimist person might modify the statement as follows.

“Currently the long term investors on here fully understand that we have nothing yet.”

This sums up my position, and perhaps that of other LTIs.

Perhaps Thursday’s statement might give us some indication as to whether 14 months of holding, and adding more shares in my case, might eventually prove to be a good investment strategy?

GLALTIs.

“Looks like we are heading into the 4s ?”

Would you kindly add some rationale to your comment please! This is an investment forum, and comments of that nature ought to be backed up with your reasoning. Otherwise why bother?

My interpretation is that current and future planning will be focused on the development of SNG001 as a broad spectrum antiviral agent, which will subsequently be included, with other remedies, in planning for future pandemic outbreaks? Designing a trial for the former is a major project and may well be beyond the capabilities of the company as it stands? If my optimism is not misguided, the spadework undertaken over the past 14 months have resulted in Synairgen being, at least, on the radar of a large pharmaceutical entity? Therein rests the limit of my deduction from the information at hand. Whether this will result in a trial partnership, moving forward to a JV and licensing deal, or whether a T/O is possible further ahead is impossible to predict at the present time?

My aspiration is for a positive announcement which will move Synairgen out of the dismal share price trough in which the company has remained for most of the last 14 months. I concur with others that serious questions will need to be asked if there isn’t an operations update on the CEO’s unhelpful New Year statement to accompany the end of year interim results?

I would favour the current CEO leading the company to a successful outcome. Whether he and his leadership team are able to deliver remains to be seen?

Roll on next Thursday’s RNS whatever it contains. As investors, there has been a serious dearth of revenue changing information since the last trial failure. The company has a good cache of analysed data from its trials at its disposal. Unfortunately, this is of little value, as regards its valuation, until Synairgen can put it to optimal use resulting in a marketable product.

GLALTIs

dactions.

Your last contribution describes my worst case scenario, which I am trying to keep at the back of my mind.

However, it makes little sense that Synairgen’s well -orchestrated campaign of presentations at directly relevant high-level conferences, sometimes with consultants accompanying company personnel, will lead to nothing?

Likewise the Comms department have been busy and a stream of relevant high-level product based information has been relentlessly presented in a variety of formats for well over 6 months. When I wrote to Brooke Clarke last Summer, she advised me to keep an eye on twitter/LinkedIn during the following months for further information. Her advice was an understatement of what eventually emerged. They have leapt on every opportunity to keep their high level multi-media communications flowing.

You are right that there hasn’t been a revenue changing update, which we are all most interested in, since February 2022. I remain optimistic that one might follow, but one never knows?

My aspiration is perfectly described by Doc.Daneeka’s excellent post yesterday. It is best to retain one’s optimism, although that is all I have until there is a concrete update from the company.

ATB and GLALTIs.

Thank you Fruits. I am relieved to find out that the term from north of the border doesn't apply here. You have introduced me to a colloquialism, which I shall now use when applicable.

"Negative Neds"?

I was curious when I saw this term used to describe some contributors, as I hadn't seen it used before.
Is this the correct definition?
NED is a derogatory term applied in Scotland to hooligans, louts or petty criminals. NED is the acronym for a "Non- Educated Delinquent"

Let's Keep Doc.Daneeka's message from earlier today in focus.

IMHO, this is the best contribution that I have read on this forum in a long while.

"Let's try to tread the middle ground for the next week or so. No sense in getting too excited or being too downbeat. We know all of the permutations and now the drug should be a strong candidate for more than one trial. Mustn't get ourselves to the point where no significant news ends up as a disaster. That's what the traders are hoping for. If STRIVE is still out there it will arrive in its own time. If TOs or JVs are in the offing they will come with a thunderclap from a clear blue sky."

MrCosts’ comments are receiving too much attention. Months ago, I commented that I found his continuous negativity boring and repetitive. He replied that he would persist until the company contributed definite information. Since then, I have failed to find a flaw in his statements, and he continues to be polite when replying to comments where that politeness is not always reciprocated.

I should share that I stopped using another Synairgen forum due to the personal abuse that I received from a contributor. The same individual regularly made disparaging comments about others on this forum. That situation was resolved months ago, when I stopped using the forum. I still take an occasional peek, and it seems that most of the aforementioned trolling has ceased.

Should anyone find MrCosts’ comments to be inappropriate, why not simply apply a filter, and stop replying to them? My experience has proven that it is best to ignore a contributor should you find his/her comments to be inappropriate, or distasteful in my experience on the other forum.

Thank you Doc.Daneeka for that eloquent summary. It is an exact statement of the current situation. We will need to wait patiently and see what develops ?

Naewise. Although I am urging caution, I am optimistic that something good may yet emerge from this investment? The scientific evidence underpinning the product is unequivocal. My doubt is whether the company’s executives are able to negotiate the necessary partnerships to eventually bring the product to market? The jury is still out until I hear otherwise? It is best to retain some optimism for the time being.

ATB and GLALTIs.

linandy1..

I have just followed up on your comment with a piece of research about convertible loan notes.

I am sharing this in case anyone is interested in finding out more about this method of financing small startup companies. The information on the link is simplified and takes minutes to read.

https://www.informdirect.co.uk/business-finance/convertible-loan-notes-clns/

Is the theory that the CEO, who holds a large % of the company’s shares, may be be downwardly manipulating the share price to achieve more profit via CLNs a credible one? I would be disappointed should this turn out to be the case.

GLALTIs

Wigster. After giving the matter some thought, I have arrived at the same conclusion as you. It is best not to get too carried away by the possible outcomes suggested by credible contributors on this forum.

Most LTIs saw a 90%+ depreciation in their SNG investment as a result of the believable sensible scenario that had been built up around the Sprinter trial. I am of the opinion that poor planning and poor decision making brought about that downfall. It is the same team that is currently engaged in planning the future of the company!

However, if after 14 months of activity, there is nothing more than a statement of the cash surplus, and a vague description of the company’s current activity, then serious questions will need to be asked at the AGM. I remain optimistic that something might be announced next week? Until we get that feedback, it is best not to get too expectant.

GLALTIs.

“Imaging Biometrics and Prism Clinical Imaging have partnered to provide brain mapping and analysis tools for clinical use in diagnosing brain disease and guiding treatment.
The companies both offer specialized technologies for patients with brain tumors and other neurological disorders, including functional MRI and diffusion tensor imaging as well as tools to combine these with PET.
Prism's products identify the tumor site and guide clinicians to it. Imaging Biometrics products then highlight the most aggressive portions of the tumor -- key for targeting surgical removal -- the companies said. They added that this combination allows physicians to remove a tumor while maximally preserving brain function.”

“the percentage of the Company’s issued share capital that is not in public hands is 30.7%”

This was the case the last time I checked months ago. It comprises the % of shares held both by TFG Holdings and Synairgen employees. It may be significant that the senior managers who recently joined the company have no shares, although there are significant share options available for them to take up at an appropriate point?

Perhaps the change in the website header to “TR-1/Options Press Releases” may be significant? Perhaps not ? As always, Trinityman’s recent label of Synairgen investors as “mushrooms” in recognition of the CEO’s management style, remains appropriate.

A quick search yielded the following. “The job you are trying to view has expired. Please perform a new search to find current jobs.”

I am as much in the dark as ever about this. Perhaps the CEO will provide clarity should we receive a comprehensive strategy update to accompany next week’s end of year audit?

https://www.simplyhired.com/job/BMyWirEy1xHCtWv2SiR8LKWdq05zbJ7YLS4xotXpQRu1hY3X4nuGaw

FTC7. “It’s just a bit of business as usual marketing.”

I believe that there is more to it than that. There has been persistent assertive marketing emphasising the same central message through different channels for more than 6 months.

There are contributors to this forum who are more qualified than myself to assess as to where this might lead? Surely no company would go to such lengths - regular quality twitter/LinkedIn messaging, a round table SciAm conversation, podcasts, animations etc for no good purpose? I am reassured to find that other contributors are drawing the same conclusion as myself. To add balance, I am not surprised to discover some cynicism and doubt shown by some investors on twitter, as well as on this forum. We have been patiently waiting for nearly 14 months for a significant piece of news to effect a paradigm change in the way that the non-invested perceive this company. IMHO Synairgen need to add to the CEO’s new year message prior to the coming AGM. I remain optimistic that we may hear something before then?

GLALTIs.

The fluctuating trades and their effect on the share price is meaningless from the LTI perspective.

As in the case of all my current investments, a significant piece of news is needed in order to escalate the share price from its current trading level.

I remain optimistic, but owing to the previous misleading information from the company, and AZ in particular, it is difficult to put a time scale on this investment finally coming to fruition? Perhaps my judgement is harsh, and the delay is due to the severe effect that recent catastrophic events still have on global economies.

I intend to hold my relatively small investment, purchased @ 0.018GBP ave ( currently 66% down ) at least until the next piece of significant news arrives. I remain optimistic in an eventual staggered launch of this business, and with it an increase in the share price. My target sell price is currently a modest 0.025GBP. I have the time as well as the patience for this to come about.

GLALTIs.

I do not believe that the frenetic Synairgen LinkedIn/ twitter publicity is continuing without good reason? New positive messages are now arriving virtually on a daily basis. No new information but a continuous reiteration of a focused message in different forms.

I would not be surprised if Synairgen had something special to inform investors next week? I remain optimistic, but wouldn’t be too disappointed if it turns out to be yet another false dawn.

There has been some interesting speculation on this forum recently. I look forward to finding out whether there will be something added to the end of year statement next Thursday.

GLALTIs.

The evidence of this continues to accumulate, without market reaction. What has the share price stagnated at the current level for so long?

https://www.linkedin.com/posts/imaging-biometrics-llc_braintumors-mri-gbm-activity-7053875103146676224-ntnP?utm_source=share&utm_medium=member_ios